Cell-Free Tumor DNA Dominant Clone Allele Frequency Is Associated With Poor Outcomes in Advanced Biliary Cancers Treated With Platinum-Based Chemotherapy.

MLA

Uson Junior, Pedro Luiz Serrano, et al. “Cell-Free Tumor DNA Dominant Clone Allele Frequency Is Associated With Poor Outcomes in Advanced Biliary Cancers Treated With Platinum-Based Chemotherapy.” JCO Precision Oncology, vol. 6, June 2022, p. e2100274. EBSCOhost, https://doi.org/10.1200/PO.21.00274.

APA

Uson Junior, P. L. S., Majeed, U., Yin, J., Botrus, G., Sonbol, M. B., Ahn, D. H., Starr, J. S., Jones, J. C., Babiker, H., Inabinett, S. R., Wylie, N., Boyle, A. W. R., Bekaii-Saab, T. S., Gores, G. J., Smoot, R., Barrett, M., Nagalo, B., Meurice, N., Elliott, N., … Borad, M. J. (2022). Cell-Free Tumor DNA Dominant Clone Allele Frequency Is Associated With Poor Outcomes in Advanced Biliary Cancers Treated With Platinum-Based Chemotherapy. JCO Precision Oncology, 6, e2100274. https://doi.org/10.1200/PO.21.00274

Chicago

Uson Junior, Pedro Luiz Serrano, Umair Majeed, Jun Yin, Gehan Botrus, Mohamad Bassam Sonbol, Daniel H Ahn, Jason S Starr, et al. 2022. “Cell-Free Tumor DNA Dominant Clone Allele Frequency Is Associated With Poor Outcomes in Advanced Biliary Cancers Treated With Platinum-Based Chemotherapy.” JCO Precision Oncology 6 (June): e2100274. doi:10.1200/PO.21.00274.